Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLR325 infusion in chronic stable heart failure
NL-OMON46128Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2018
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing CLR325 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2018; status: active, not recruiting.
02
Drugs
CLR325
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON46128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46128.